Kymera Therapeutics Inc (KYMR) — Cash Flow-to-Debt Ratio
Kymera Therapeutics Inc (KYMR) has a Cash Flow-to-Debt Ratio of -0.69x as of March 2026, meaning its operating cash flow of $-88.84 Million could theoretically repay -1% of its total liabilities ($129.38 Million) in one year. Explore Kymera Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kymera Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Kymera Therapeutics Inc across 8 annual periods. Also explore KYMR current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Kymera Therapeutics Inc (2018–2025)
Year-by-year debt coverage analysis for Kymera Therapeutics Inc. For market capitalisation and broader financial context, see Kymera Therapeutics Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.43x | $-232.89 Million | $163.15 Million | ▼ -4.5% |
| 2024 | -1.37x | $-194.50 Million | $142.42 Million | ▼ -140.1% |
| 2023 | -0.57x | $-102.83 Million | $180.79 Million | ▲ +58.0% |
| 2022 | -1.35x | $-153.09 Million | $112.98 Million | ▼ -53.7% |
| 2021 | -0.88x | $-128.95 Million | $146.27 Million | ▼ -303.4% |
| 2020 | 0.43x | $88.13 Million | $203.29 Million | ▲ +362.7% |
| 2019 | 0.09x | $17.91 Million | $191.11 Million | ▲ +141.3% |
| 2018 | -0.23x | $-17.86 Million | $78.67 Million | — |